Catalog No.: PC-72172Not For Human Use, Lab Use Only.
IMR-687 (IMR687, Tovinontrine) is a novel, potent and selective phosphodiesterase-9 (PDE-9) inhibitor with IC50 of 8.19 nM and 9.99 nM against PDE9A1 and PDE9A2, respectively.
IMR-687 (IMR687, Tovinontrine) is a novel, potent and selective phosphodiesterase-9 (PDE-9) inhibitor with IC50 of 8.19 nM and 9.99 nM against PDE9A1 and PDE9A2, respectively.
IMR-687 (Tovinontrine) displays>800-fold greater potency than PDE1A3, PDE1B, PDE1C, PDE5A2 (IC50 values >8 uM).
IMR-687 (Tovinontrine) recapitulates the cGMP and fetal hemoglobin (HbF) induction mechanism of hydroxyurea (HU) in erythroid cells.
Treatment of phosphodiesterase 9A inhibitor (IMR-687, Tovinontrine) in sickle mice for 30 days results in fetal hemoglobin (HbF) induction, reduced hemolysis and reticulocytosis, as well as immune cell activity.
IMR-687 (Tovinontrine) increases F-cells in patient-derived sickle cell disease (SCD) CD36+ cells, reduces vessel-occlusion in the Townes-HbSS sickle cell disease model.
